Global medicinal cannabis company, Veritas Pharma Inc. has announced the completion of a clinical trial by their Puerto Rican subsidiary to test the efficacy of vaporized CTL-X, their specific cannabis strain mix, in the treatment of acute pain.
San Juan-based FDI Clinical Research conducted the randomized, double-blinded, cross-over trial, which began in late 2018.
CTL-X previously underwent two years of preclinical testing at Veritas’ research division, Cannavert Therapeutics Ltd. at the University of British Columbia.
“From this study, we will be able to provide real scientific and evidence-based data on the use of cannabis for medical purposes for treatment of acute pain,” said Veritas Medical Director, Dr. Scott Alexander. “We believe that for millions of people suffering from acute pain, vaporized cannabis can potentially reduce the need for other medications, including opioids.”
Dr. Alexander says that the study results will give clinicians a better understanding of specific dosage and delivery for acute pain and encourage more research to identify risks and benefits of whole plant cannabinoid use in complementary therapy.
With the trial phase completed, Veritas and FDI will take the next three months to analyze the results and submit a scientific report for publication detailing preliminary efficacy data on CTL-X compared to a placebo, dosage guidelines, and safety and tolerability data on side effects and adverse reactions.
